Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Company Overview

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 12,165 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANTH Stock Analysis - Frequently Asked Questions

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) announced its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.09.

When did Anthera Pharmaceuticals' stock split?

Anthera Pharmaceuticals's stock reverse split on the morning of Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anthera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 3/05/2018
• Today: 5/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ANTH
• CIK: 1316175
• Web: www.anthera.com
• Phone: (410) 350-1839
• Fax: 510-856-5597
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.92